Illumina (NASDAQ:ILMN) had its price target lifted by Leerink Swann from $250.00 to $276.00 in a report released on Wednesday. The firm presently has an “outperform” rating on the life sciences company’s stock. Leerink Swann’s price target points to a potential upside of 18.64% from the stock’s previous close.
Other research analysts also recently issued research reports about the company. First Analysis upgraded Illumina from an “equal weight” rating to an “overweight” rating and set a $277.00 price target on the stock in a research note on Wednesday. Canaccord Genuity restated a “buy” rating and set a $265.00 price target (up previously from $255.00) on shares of Illumina in a research note on Wednesday. Wells Fargo & Co reiterated a “market perform” rating and issued a $205.00 target price (up from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $252.00 target price on the stock in a research note on Tuesday, December 5th. Finally, BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company. Illumina currently has a consensus rating of “Buy” and an average price target of $237.83.
Illumina (NASDAQ ILMN) traded down $8.54 during trading hours on Wednesday, reaching $232.64. The company had a trading volume of 1,760,000 shares, compared to its average volume of 900,391. The stock has a market cap of $33,970.00, a P/E ratio of 47.19, a PEG ratio of 3.24 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a 12-month low of $156.50 and a 12-month high of $248.97.
In related news, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now directly owns 9,088 shares in the company, valued at $2,058,886.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $210.59, for a total value of $4,211,800.00. Following the completion of the sale, the director now owns 536,717 shares in the company, valued at $113,027,233.03. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,921 shares of company stock worth $29,309,093. Company insiders own 0.89% of the company’s stock.
Several institutional investors have recently bought and sold shares of ILMN. Capital World Investors boosted its stake in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Illumina by 8.8% in the fourth quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock valued at $964,114,000 after buying an additional 355,200 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Illumina by 1,556.2% in the second quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after buying an additional 310,084 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Illumina in the second quarter valued at approximately $45,098,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Illumina by 371.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock valued at $46,355,000 after buying an additional 167,206 shares in the last quarter. Hedge funds and other institutional investors own 91.71% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Leerink Swann Boosts Illumina (ILMN) Price Target to $276.00” was first reported by American Market News and is the property of of American Market News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/31/leerink-swann-boosts-illumina-ilmn-price-target-to-276-00.html.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
